47 related articles for article (PubMed ID: 30196990)
1. Challenges in the management of checkpoint inhibitor induced liver injury.
Cavasi A; Ștoleru I; Buziaș M; Rusu I
J Gastrointestin Liver Dis; 2023 Dec; 32(4):560-562. PubMed ID: 38147609
[No Abstract] [Full Text] [Related]
2. Hyperacute Onset of Immune Checkpoint Inhibitor-Related Acute Interstitial Nephritis.
Tawhari I; Fenton SE; Sosman JA; Sustento-Reodica N; Kanwar YS; Aggarwal V
Kidney Int Rep; 2020 Nov; 5(11):2084-2088. PubMed ID: 33163728
[No Abstract] [Full Text] [Related]
3. Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency.
Hanna RM; Selamet U; Bui P; Sun SF; Shenouda O; Nobakht N; Barsoum M; Arman F; Rastogi A
Case Rep Nephrol Dial; 2018; 8(2):171-177. PubMed ID: 30197906
[TBL] [Abstract][Full Text] [Related]
4. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
Ready N; Farago AF; de Braud F; Atmaca A; Hellmann MD; Schneider JG; Spigel DR; Moreno V; Chau I; Hann CL; Eder JP; Steele NL; Pieters A; Fairchild J; Antonia SJ
J Thorac Oncol; 2019 Feb; 14(2):237-244. PubMed ID: 30316010
[TBL] [Abstract][Full Text] [Related]
5. Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic.
Melms JC; Thummalapalli R; Shaw K; Ye H; Tsai L; Bhatt RS; Izar B
J Immunother Cancer; 2018 Sep; 6(1):89. PubMed ID: 30208947
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
7. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events.
Herrmann SM; Perazella MA
Kidney Int Rep; 2020 Aug; 5(8):1139-1148. PubMed ID: 32775813
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitor-related renal vasculitis and use of rituximab.
Mamlouk O; Lin JS; Abdelrahim M; Tchakarov AS; Glass WF; Selamet U; Buni M; Abdel-Wahab N; Abudayyeh A
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32718987
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression.
Martinez Valenzuela L; Gómez-Preciado F; Guiteras J; Antón Pampols P; Gomà M; Fulladosa X; Cruzado JM; Torras J; Draibe J
J Transl Med; 2024 May; 22(1):421. PubMed ID: 38702780
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
Khan OF; Monzon J
Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
[TBL] [Abstract][Full Text] [Related]
12. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
13. AKI in Patients Receiving Immune Checkpoint Inhibitors.
Perazella MA; Sprangers B
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1077-1079. PubMed ID: 31048326
[No Abstract] [Full Text] [Related]
14. Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature.
Saiki R; Katayama K; Saiki H; Fukumori A; Tsujimoto K; Yamawaki M; Tanaka F; Takahashi D; Oda K; Suzuki Y; Murata T; Dohi K
BMC Nephrol; 2024 Feb; 25(1):51. PubMed ID: 38336610
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature.
Hino C; Nishino K; Pham B; Jeon WJ; Nguyen M; Cao H
Front Immunol; 2022; 13():993622. PubMed ID: 36052087
[TBL] [Abstract][Full Text] [Related]
17. The nephrotoxicity of immune checkpoint inhibitor-based combinations.
El Rassy E; Bakouny Z; Yared F; Chelala DN; El Karak F; Ghosn M
Eur J Cancer; 2018 Nov; 103():274-278. PubMed ID: 30196990
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
